EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes

Angela X Chen iD, Robert Fletcher, Brendon L Neuen iD, Bruce Neal iD, Clare Arnott iD

Diabetes, Obesity and Metabolism · 2024-10 · 26 (S5) · 5-13

DOI: 10.1111/dom.15751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.07.2024. Verfasst von Angela X Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Program, The George Institute of Global Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Canagliflozin, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To provide an overview of the primary outcomes and key clinical implications of the CANVAS Program and CREDENCE trial, which were event‐driven, double‐blind randomized controlled trials that established the efficacy and safety of canagliflozin in those with type 2 diabetes (T2D) and high cardiovascular risk (CV) or albuminuric chronic kidney disease (CKD). Methods and Results The CANVAS programme (CANVAS and CANVAS‐R trials) randomized 10 142 people with T2D and high CV risk to canagliflozin or placebo and followed them for a median of 126 weeks. The primary efficacy outcome was met, with canagliflozin treatment associated with a 14% reduction in major adverse CV events (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.75 to 0.97; p < 0.001) as compared to placebo. The CREDENCE trial randomized 4401 individuals with T2D and albuminuric CKD to canagliflozin or placebo and followed them for 109 weeks. The CREDENCE trial also met its primary endpoint; canagliflozin treatment was associated with a 30% reduction in the composite of kidney failure, sustained doubling of serum creatinine level, or death from kidney or CV causes (HR 0.70, 95% CI 0.59 to 0.82; p < 0.001). Substantial reductions in hospitalization for heart failure (CANVAS: HR 0.67, 95% CI 0.52 to 0.87; CREDENCE: HR 0.61, 95% CI 0.47 to 0.80) and other key CV and kidney outcomes were also identified. Relative clinical benefits were consistent across subgroups defined by baseline age, sex, kidney function and history of CV disease but absolute benefits were greatest in those at highest baseline risk. Total serious adverse events were less common with canagliflozin treatment. Concerns about amputation and fracture risk observed in the CANVAS Program were not seen in CREDENCE and appear to have been spurious chance findings.

Conclusion

Canagliflozin reduced important CV, kidney and mortality outcomes in those with T2D and high CV risk or CKD across diverse patient groups, with a good safety profile. Taken together with the other sodium‐glucose cotransporter‐2 inhibitor CV and renal outcomes trials, these landmark findings have changed the treatment landscape for patients worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsFemaleHumansMaleDiabetic AngiopathiesDiabetic NephropathiesDouble-Blind MethodRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

CanagliflozinSGLT2 inhibitorantidiabetic drugcardiovascular diseaseclinical trialrandomized trial

Substanzen

CanagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Cardiovascular Program, The George Institute of Global Health, University of New South Wales, Sydney, Australia.
  • Sydney Medical School, University of Sydney, Sydney, Australia.
  • Department of Endocrinology and Diabetes, Westmead Hospital, Sydney, Australia.
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
  • Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.

ORCID-Profile: Angela X Chen, Brendon L Neuen, Bruce Neal, Clare Arnott

Zitieren

APA

Chen, A. X., Fletcher, R., Neuen, B. L., Neal, B., & Arnott, C. (2024). An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 26(S5), 5-13. https://doi.org/10.1111/dom.15751

Vancouver

Chen AX, Fletcher R, Neuen BL, Neal B, Arnott C. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2024;26(S5):5-13. doi:10.1111/dom.15751

BibTeX
@article{Chen2024,
  author = {Chen, Angela X and Fletcher, Robert and Neuen, Brendon L and Neal, Bruce and Arnott, Clare},
  title = {An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {S5},
  pages = {5--13},
  doi = {10.1111/dom.15751}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche